For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Dihexa vs DSIP

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

DihexaDSIP
CategoryNootropic & CognitiveNootropic & Cognitive
Also known asPNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amideDelta Sleep Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
EvidencePreclinical onlyResearch-stage
Dosing range10mg–20mg mg, Once daily (or every other day — long-lasting effects)100mcg–500mcg mcg, Once daily (evening) or every other day
AdministrationOral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common)Subcutaneous injection, Intranasal, Intravenous (clinical studies)
Key side effectsPotential for pro-proliferative effects — HGF/c-Met pathway promotes cell growth (theoretical cancer concern at high doses), Headache (uncommon), Mental fatigue if overdosed, Long half-life means effects accumulate — take every other day initiallyGenerally well-tolerated, Daytime drowsiness if dosed in morning, Mild headache, Altered dream quality (common)
Cited sources2 references3 references

Key differences

  • Evidence level differs: Dihexa is preclinical only, while DSIP is research-stage.
  • Administration: Dihexa — Oral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common); DSIP — Subcutaneous injection, Intranasal, Intravenous (clinical studies).
  • Dosing units differ: Dihexa is dosed in mg, DSIP in mcg — they operate at different scales.
  • Frequency: Dihexa is typically Once daily (or every other day — long-lasting effects); DSIP is Once daily (evening) or every other day.
  • Research depth: this profile cites 2 sources for Dihexa vs 3 for DSIP.

How each works

Dihexa

Dihexa (PNB-0408) was developed by Joseph Harding and colleagues at WSU as a metabolically stable angiotensin IV analog. It binds hepatocyte growth factor (HGF), potentiating its interaction with the c-Met receptor — a pathway critical for dendritic branching, synapse formation, and synaptic plasticity. In rodent Alzheimer's and scopolamine-impaired models, Dihexa restored cognitive performance at doses ~7 orders of magnitude lower than BDNF. It readily crosses the blood-brain barrier due to its lipophilicity, unlike BDNF itself.

DSIP

DSIP does not directly trigger sleep in the simple sense originally proposed — more recent research indicates it modulates the neuroendocrine environment that facilitates sleep. Key findings: it reduces ACTH-driven cortisol elevation under stress, increases GH secretion in some models, and attenuates withdrawal severity in opioid and alcohol dependence (mechanisms unclear). DSIP demonstrates antioxidant effects and has cardioprotective properties in ischemic preconditioning models in animals. Its unique resistance to most peptidases (attributed to its unusual conformation) gives it a relatively long half-life for a nonapeptide.

Read the full Dihexa profileRead the full DSIP profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.